Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Carpenter

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Nature|May 12, 2012
Policy reform: Strengthen and stabilize the FDADaniel Carpenter
Journal of Health Politics, Policy and Law|August 27, 2004
Staff resources speed FDA drug review: a critical analysis of the returns to resources in approval regulationDaniel Carpenter
JAMA Internal Medicine|October 30, 2013
Can expedited FDA drug approval without expedited follow-up be trusted?Daniel Carpenter
Health Affairs (Project Hope)|October 20, 2005
A proposal for financing postmarketing drug safety studies by augmenting FDA user feesDaniel Carpenter
Journal of Health Politics, Policy and Law|December 30, 2006
Forcing pharmaceutical history into boxesDaniel Carpenter
The Virtual Mentor : VM|December 25, 2012
Gatekeeping and the FDA's Role in Human Subjects ProtectionDaniel Carpenter
The Virtual Mentor : VM|December 14, 2012
Reputation, gatekeeping, and the politics of post-marketing drug regulationDaniel Carpenter
The New England Journal of Medicine|April 13, 2017
Scott Gottlieb and the Credibility of U.S. TherapeuticsDaniel Carpenter
AMA Journal of Ethics|March 3, 2023
What Should Be Clinicians' Roles in Regulatory Assessment of Prospective Interventions' Risks of Exacerbating Inequity?Anushka Bhaskar, Daniel Carpenter
JAMA|May 19, 2011
A unique researcher identifier for the Physician Payments Sunshine ActDaniel Carpenter, Steven Joffe
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Nature|May 12, 2012
Policy reform: Strengthen and stabilize the FDADaniel Carpenter
Journal of Health Politics, Policy and Law|August 27, 2004
Staff resources speed FDA drug review: a critical analysis of the returns to resources in approval regulationDaniel Carpenter
JAMA Internal Medicine|October 30, 2013
Can expedited FDA drug approval without expedited follow-up be trusted?Daniel Carpenter
Health Affairs (Project Hope)|October 20, 2005
A proposal for financing postmarketing drug safety studies by augmenting FDA user feesDaniel Carpenter
Journal of Health Politics, Policy and Law|December 30, 2006
Forcing pharmaceutical history into boxesDaniel Carpenter
The Virtual Mentor : VM|December 25, 2012
Gatekeeping and the FDA's Role in Human Subjects ProtectionDaniel Carpenter
The Virtual Mentor : VM|December 14, 2012
Reputation, gatekeeping, and the politics of post-marketing drug regulationDaniel Carpenter
The New England Journal of Medicine|April 13, 2017
Scott Gottlieb and the Credibility of U.S. TherapeuticsDaniel Carpenter
AMA Journal of Ethics|March 3, 2023
What Should Be Clinicians' Roles in Regulatory Assessment of Prospective Interventions' Risks of Exacerbating Inequity?Anushka Bhaskar, Daniel Carpenter
JAMA|May 19, 2011
A unique researcher identifier for the Physician Payments Sunshine ActDaniel Carpenter, Steven Joffe
Pageof 7